This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a colleague Similar articles in this journal Similar articles in Web of Science Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Web of Science (16) Citing Articles via Google Scholar Google Scholar Articles by Koster, A. Articles by Spiess, B. D. Search for Related Content PubMed PubMed Citation Articles by Koster, A. Articles by Spiess, B. D. Related Collections Cardiovascular Heart Equipment

---

TECHNICAL COMMUNICATION

An Assessment of Different Filter Systems for Extracorporeal Elimination of Bivalirudin: An In Vitro Study

Andreas Koster, MD^*, Derek Chew, MD, Marcus Gründel, MD^*, Harald Hausmann, MD, Onnen Grauhan, MD, Herman Kuppe, MD^*, and Bruce D. Spiess, MD

Departments for *Anesthesia and Thoracic and Cardiovascular Surgery, Deutsches Herzzentrum Berlin, Berlin, Germany; Department of Cardiology, Flinders Medical Center, South Australia, Australia; and Department of Cardiothoracic Anesthesia, Virginia Commonwealth University, Richmond, Virginia

Address correspondence and reprint requests to Dr. Andreas Koster, Deutsches Herzzentrum Berlin, Augustenburger Platz 1, D-13353 Berlin, Germany. Address e-mail to koster{at}dhzb.de

IMPLICATIONS: Bivalirudin is a new, direct thrombin inhibitor. We investigated the extracorporeal elimination rate of different hemofilters and one plasmapheresis filter for bivalirudin. Our data show that bivalirudin can be effectively eliminated via hemofiltration and plasmapheresis, although there were significant differences in the elimination rates among the filter systems investigated.

This article has been cited by other articles:

				I. Apostolidou, M. F. Sweeney, E. Missov, L. D. Joyce, R. John, and R. C. Prielipp Acute Left Atrial Thrombus After Recombinant Factor VIIa Administration During Left Ventricular Assist Device Implantation in a Patient with Heparin-Induced Thrombocytopenia Anesth. Analg., February 1, 2008; 106(2): 404 - 408. [Abstract] [Full Text] [PDF]

				A. F. Merry Focus on Thrombin: Alternative Anticoagulants Seminars in Cardiothoracic and Vascular Anesthesia, December 1, 2007; 11(4): 256 - 260. [Abstract] [PDF]

				A. Koster, T. Hentschel, T. Groman, H. Kuppe, R. Hetzer, S. Harder, and K.-G. Fischer Argatroban anticoagulation for renal replacement therapy in patients with heparin-induced thrombocytopenia after cardiovascular surgery J. Thorac. Cardiovasc. Surg., May 1, 2007; 133(5): 1376 - 1377. [Full Text] [PDF]

				R. L. Cain, B. D. Spiess, M. Nelson, A. Deanda Jr, H. L. McCarthy, and J. A. Green Bivalirudin Anticoagulation for a Patient with Hypercoagulable Immune Syndromes Undergoing Mitral Valve Surgery Ann. Thorac. Surg., June 1, 2006; 81(6): 2308 - 2310. [Abstract] [Full Text] [PDF]

				A. Koster, D. Chew, F. Merkle, M. Gruendel, M. Jurmann, H. Kuppe, and R. Oertel Extracorporeal Elimination of Large Concentrations of Tirofiban by Zero-Balanced Ultrafiltration During Cardiopulmonary Bypass: An In Vitro Investigation Anesth. Analg., October 1, 2004; 99(4): 989 - 992. [Abstract] [Full Text] [PDF]

				G. Stratmann, A. M. deSilva, E. E. Tseng, J. Hambleton, M. Balea, A. J. Romo, M. J. Mann, N. L. Achorn, W. F. Moskalik, and C. W. Hoopes Reversal of Direct Thrombin Inhibition After Cardiopulmonary Bypass in a Patient with Heparin-Induced Thrombocytopenia Anesth. Analg., June 1, 2004; 98(6): 1635 - 1639. [Abstract] [Full Text] [PDF]

				J. A. Green, C. L. Cooper, O. A. Falcucci, A. Safwat, T. Slaughter, B. D. Spiess, and V. G. Nielsen Argatroban for Off-Pump Coronary Artery Bypass Surgery * Response Anesth. Analg., October 1, 2003; 97(4): 1201 - 1202. [Full Text] [PDF]